Dysregulation of matrix metalloproteinases and their tissue inhibitors is related to abnormality of left ventricular geometry and function in streptozotocin-induced diabetic minipigs

International Journal of Experimental Pathology

Volumn 89, Issue 2, 2008, Pages 125-137

  Lu, Lin ^a   Zhang, Qi ^a   Pu, Li Jin ^a   Peng, Wen Hui ^a   Yan, Xiao Xiang ^a   Wang, Lin Jie ^a   Chen, Qiu Jing ^a   Zhu, Zheng Bing ^a   Michel, Jean Baptiste ^b   Shen, Wei Feng ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b INSERM   (France)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Echocardiography; Hypertrophy; Left ventricular function; Matrix metalloproteinase; Tissue inhibitor of matrix metalloproteinase; Urokinase type plasminogen activator

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; COLLAGEN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; STREPTOZOCIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UROKINASE; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA INTIMA; ARTICLE; BLOOD LEVEL; BLOOD VESSEL DIAMETER; BLOOD VESSEL WALL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DOPPLER ECHOCARDIOGRAPHY; ENZYME ACTIVITY; HEART DISEASE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART VENTRICLE SEPTUM; MALE; MINIPIG; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; THICKNESS; VASCULAR FIBROSIS; ZYMOGRAPHY;

ANIMALS; AORTA; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION REGULATION; HEART VENTRICLES; MALE; MATRIX METALLOPROTEINASES; NATRIURETIC PEPTIDE, BRAIN; RNA, MESSENGER; SWINE; SWINE, MINIATURE; TISSUE CULTURE TECHNIQUES; TISSUE INHIBITOR OF METALLOPROTEINASES; TUNICA INTIMA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 40549096770     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2008.00579.x     Document Type: Article

References (44)

1. Asbun J., Manso A.M., Villarreal F.J. (2005) Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E. Am. J. Physiol. Heart Circ. Physiol. 288, H227 H234.
2. Badier-Commander C., Verbeuren T., Lebard C., Michel J.B., Jacob M.P. (2000) Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J. Pathol. 192, 105 112.
3. Bell D.S. (2003) Diabetic cardiomyopathy. Diabetes Care 26, 2949 2951.
4. Bollano E., Omerovic E., Svensson H., Waagstein F., Fu M. (2007) Cardiac remodeling rather than disturbed myocardial energy metabolism is associated with cardiac dysfunction in diabetic rats. Int. J. Cardial. 114, 195 201.
5. Bradford M.M. (1976) Rapid and sensitive method for quantification of microgram quantities of protein utilizing principle of protein-dye binding. Anal. Biochem. 72, 248.
6. Carvalho R.F., Dariolli R., Justulin Junior L.A. et al. (2006) Heart failure alters matrix metalloproteinase gene expression and activity in rat sheletal muscle. Int. J. Exp. Pathol. 87, 437 443.
7. Christoffersen C., Goetze J.P., Bartels E.D. et al. (2002) Chamber-dependent expression of brain natriuretic peptide and its mRNA in normal and diabetic pig heart. Hypertension 40, 54 60.
8. Chung A.W., Hsiang Y.N., Matzke L.A., McManus B.M., van Breemen C., Okon E.B. (2006) Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ. Res. 99, 140 148.
9. Chung A.W., Luo H., Tejerina T., van Breemen C., Okon E.B. (2007) Enhanced cell cycle entry and mitogen-activated protein kinase-signaling and downregulation of matrix metalloproteinase-1 and -3 in human diabetic arterial vasculature. Atherosclerosis 195, e1 e8.
10. Creemers E., Cleutjens J., Smits J., Daemen M. (2001) Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ. Res. 89, 201 210.
11. Derosa G., Avanzini M.A., Geroldi D. et al. (2005) Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabetes Res. Clin. Pract. 70, 119 125.
12. Derosa G., Cicero A.F., Scalise F. et al. (2007) Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium 14, 45 51.
13. Fehrenbacher A., Steck E., Rickert M., Roth W., Richter W. (2003) Rapid regulation of collagen but not metalloproteinase 1, 3, 13, 14 and tissue inhibitor of metalloproteinase 1, 2, 3 expression in response to mechanical loading of cartilage explants in vitro. Arch. Biochem. Biophys. 410, 39 47.
14. Feigenbaum H. (1999) Echocardiography. 6th ed. Philadephia, Pa : Lea and Febiger.
15. Gillespie D.L., Fileta A.P.B., Chang A. et al. (2002) Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13. J. Surg. Res. 106, 233 238.
16. Guertl B., Noehammer C., Hoefler G. (2000) Metabolic cardiomyopathies. Int. J. Exp. Pathol. 81, 349 372.
17. Harris A.K., Hutchinson J.R., Sachidanandam K. et al. (2005) Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinase and collagen synthesis: role of endothelin-1. Diabetes 54, 2638 2644.
18. Hayashi T., Sohmiya K., Ukimura A., Endoh S., Mori T., Shimomura H. (2003) Angiotensin II receptor blockade prevents microangiopathy and preserved diastolic function in the diabetic rat heart. Heart 89, 1236 1242.
19. Jesmin S., Sakuma I., Hattori Y., Kitabatake A. (2003) Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodelling in insulin-resistant diabetic rats. Arterioscler. Thromb. Vasc. Biol. 23, 2021 2026.
20. Kadoglou N.P., Daskalopoulou S.S., Perrea D., Liapis C.D. (2005) Matrix metalloproteinases and diabetic vascular complications. Angiology 56, 173 189.
21. Kenichi M., Masanobu M., Takehiko K. et al. (2004) Renal synthesis of urokinase type-plasminogen activatior, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin- converting-enzyme inhibitor. J. Lab. Clin. Med. 144, 69 77.
22. Kimura A., Kihara T., Ohkura R., Ogiwara K., Takahashi T. (2001) Localization of bradykinin B2 receptor in the follicles of porcine ovary and increased expression of matrix metalloproteinase-3 and -20 in cultured granulose cells by bradykinin treatment. Biol. Reprod. 65, 146 1470.
23. Koike M.K., Frimm Cde C., Curi M. (2007) Low coronary driving pressure early in the course of myocardial infarction is associated with subendocardial remodelling and left ventricular dysfunction. Int. J. Exp. Pathol. 88, 279 290.
24. Lee S.W., Song K.E., Shin D.S. et al. (2005) Alterations in peripheral blood levels of TIMP-1, MMP-2 and MMP-9 in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 69, 175 179.
25. Lu L., Zhang Q., Pu L.J. et al. (2007) Elevation of tumor necrosis factor-alpha, interleukin-1beta and interleukin-6 levels in aortic intima of Chinese Guizhou Minipigs with streptozotocin-induced diabetes. Chin. Med. J. 120, 479 484.
26. Lubien E., DeMaria A., Krishnaswamy P. et al. (2002) Utility of B-natriuretic peptide in detecting diastolic dysfunction : comparison with doppler velocity recordings. Circulation 105, 595 601.
27. Maxwell P., Timms P., Chandran S., Gordon D. (2001) Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with Type 1 diabetes. Diabet. Med. 18, 777 780.
28. McDonagh T.A., Robb S.D., Murdoch D.R. (1998) Biochemical detection of left ventricular systolic dysfunction. Lancet 351, 9 13.
29. Menino A.R., Hogan A., Schultz G.A., Novak S., Dixon W., Foxcroft G.H. (1997) Expression of proteinases and proteinase inhibitors during embryo-uterine contact in the pig. Dev. Genet. 21, 68 74.
30. Moelker A.D., Baks T., van den Bos E.J. et al. (2006) Reduction in infarct size, but no functional improvement after bone marrow cell administration in a porcine model of reperfused myocardial infarction. Eur. Heart J. 27, 3057 3064.
31. Nakamura T., Matsuda T., Suzuki Y., Ureda Y., Koide H. (2003) Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic haemodialysis patients with arteriosclerosis obliterans. ASAIO J. 49, 430 434.
32. Portik-Dobos V., Anstadt M.P., Hutchinson J., Bannan M., Ergul A. (2002) Evidence for a matrix metalloproteinase in induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 51, 3063 3068.
33. Sachidanandam K., Portik-Dobos V., Harris A.K. et al. (2007) Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes. Diabetes 56, 2753 2758.
34. Seeland U., Kouchi I., Zolk O., Itter G., Linz W., Bohm M. (2002) Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts. J. Mol. Cell Cardiol. 34, 151 163.
35. Senzaki H., Paolocci N., Gluzband Y.A. et al. (2000) Beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evlving cardiac dysfunction. Circ. Res. 86, 807 815.
36. Song W.W. Ergul A. (2006) Type 2 diabetes-induced changes in vascular extracellular matrix gene expression: Relation to vessel size. Cardiovasc. Diabetol. 5, 3.
37. Stempien-Otero A., Plawman A., Meznarich J., Dvamenahalli T., Otsuka G., Dichek D.A. (2006) Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. J. Biol. Chem. 281, 15345 15351.
38. Tayebjee M.H., Lip G.Y.H., MacFadyen R.J. (2005) What role do extracellular matrix changes contribute to the cardiovascular disease burden of diabetes mellitus? Diabet. Med. 22, 1628 1635.
39. Tsutamoto T., Wada A., Maeda K. (1997) Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 350, 1347 1351.
40. Tyaqi S.C. Hayden M.R. (2003) Role of nitric oxide in matrix remodeling in diabetes and heart failure. Heart Fail Rev. 8, 23 28.
41. Westermann D., Rutschow S., Jager S. et al. (2007a) Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56, 641 646.
42. Xi S., Yin W., Wang Z. et al. (2004) A minipig model of high-fat/high-sucrose diet-induced diabetes and atherosclerosis. Int. J. Exp. Pathol. 85, 223 231.
43. Yu X., Tesiram Y.A., Towner R.A. et al. (2007) Early myocardial dysfunction in streptozotocin-induced diabetic mice : a study using in vivo magnetic resonance imaging (MRI). Cardiovasc. Diabetol. 6, 6.
44. Zhang Q., Lu L., Pu L.J. et al. (2007) Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine. Cardiovasc. Diabet. 6, 16.